Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMD3100 with Bu/Flu/ATG for SCT in AML and MDS
NCT00396968Phase 2Withdrawn
- Sponsor
- Sanofi
01
Overview
Phase 2, open-label, single-arm trial of plerixafor in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Sanofi. Primary endpoints: Safety and Tolerability of AMD3100 and Progression-Free Survival. Status: withdrawn.
02
Drugs
plerixafor
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00396968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396968.